Tarsus Pharmaceuticals (TARS) Interest & Investment Income (2019 - 2026)

Tarsus Pharmaceuticals' Interest & Investment Income history runs 6 years deep, the most recent figure standing at $3.7 million for Q1 2026.

• In Q1 2026, Interest & Investment Income rose 7.76% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at $16.0 million (up 4.33% YoY), while the FY2025 annual figure was $15.7 million, up 4.88% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $3.7 million, down from $4.0 million in the prior quarter.
• The five-year high for Interest & Investment Income was $4.2 million in Q2 2025, with the low at $297000.0 in Q2 2022.
• The 5-year median for Interest & Investment Income is $3.3 million (2024), against an average of $3.0 million.
• The sharpest annual moves came in 2022 and 2025: Interest & Investment Income jumped 13162.5% in 2022, then slipped 0.15% in 2025.
• Tarsus Pharmaceuticals' Interest & Investment Income stood at $2.1 million in 2022, then soared by 40.01% to $3.0 million in 2023, then climbed by 22.46% to $3.6 million in 2024, then advanced by 8.31% to $4.0 million in 2025, then retreated by 5.77% to $3.7 million in 2026.
• Business Quant data shows TARS's Interest & Investment Income at $3.7 million in Q1 2026, $4.0 million in Q4 2025, and $4.1 million in Q3 2025.